AAN 2022 | Why is personalized medicine important in multiple sclerosis?

Jean-Pierre Falet, MD, CM, McGill University, Montreal, Canada, comments on key goals of a personalized medicine approach in the field of multiple sclerosis (MS). As well as enabling a more informed treatment recommendation for a given patient, knowledge on which patient populations are likely to show the best responses to a drug would allow predictive enrichment in clinical trials. Clinical trials interrogating potential disease-modifying agents often assess the rate of disability progression, an outcome that changes slowly over time. Preferentially enrolling patients who are more likely to respond to the drug could overcome the need for large cohorts or long trial durations by increasing trial power. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.